<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866319</url>
  </required_header>
  <id_info>
    <org_study_id>3475-006</org_study_id>
    <secondary_id>2012-004907-10</secondary_id>
    <secondary_id>MK-3475-006</secondary_id>
    <nct_id>NCT01866319</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)</brief_title>
  <official_title>A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of 2 different dosing schedules of
      pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2
      schedules to treatment with ipilimumab in ipilimumab-na√Øve participants with unresectable or
      metastatic melanoma.

      Participants assigned to treatment with pembrolizumab could receive up to 2 years of
      treatment; if participants stopped treatment at 2 years and later experienced progression,
      they were eligible for a second course of treatment for up to 1 additional year. With
      Amendment 05, all Second Course participants will be treated with a fixed dose of
      pembrolizumab 200 mg Q3W. With Amendment 06, after the study has achieved its key objectives
      or the study has ended, participants will be discontinued from this study and enrolled in an
      extension study to continue protocol-defined assessments and treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2013</start_date>
  <completion_date type="Anticipated">July 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 24, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded independent central radiologic and clinical review using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5mm or the appearance of new lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Month 12</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. The reported percentage is estimated using a product-limit (Kaplan-Meier) method for censored data; for participants whose survival data was obtained after the data cut-off date for the interim analysis, data were censored at the date of cut-off (3 March 2015). Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR) or partial response (PR) based on blinded independent central radiologic and clinical review using RECIST 1.1. CR was defined as disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm. PR was defined as a 30% or greater decrease in the sum of diameters of target lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">834</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg/kg intravenously (IV), Q2W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive ipilimumab, 3 mg/kg IV Q3W for a total of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.</description>
    <arm_group_label>Pembrolizumab Q2W</arm_group_label>
    <arm_group_label>Pembrolizumab Q3W</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>No change with Amendment 05.</description>
    <arm_group_label>Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma
             not amenable to local therapy (excluding uveal or ocular melanoma)

          -  At least one measurable lesion

          -  No prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma
             (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant
             therapy) for melanoma (second line)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Archived tissue sample or new biopsy sample

          -  Female participants of childbearing potential must agree to use effective
             contraception from Visit 1 to 120 days after the last dose of study drug; male
             participants must agree to use an adequate method of contraception starting with the
             first dose of study drug through 120 days after the last dose of study drug

        Exclusion criteria:

          -  Prior treatment with ipilimumab or other anti-cytotoxic T-Lymphocyte Antigen 4
             (CTLA-4) agent or any anti-programmed cell death (PD-1 or PD-L2) agent

          -  Chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the
             first dose of study drug, or not recovered from adverse events caused by cancer
             therapeutics administered more than four weeks earlier

          -  Currently participating or has participated in a study of an investigational agent or
             using an investigational device within 30 days of the first dose of study drug

          -  Expected to require any other form of systemic or localized antineoplastic therapy
             while on study

          -  On any systemic steroid therapy within one week before the planned date for first dose
             of randomized treatment or on any other form of immunosuppressive medication

          -  History of a malignancy (other than the disease under treatment in the study) within 5
             years prior to first study drug administration, excluding adequately treated Stage 1
             or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the cervix
             or breast, or other in situ cancers.

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             participants with previously treated brain metastases are eligible

          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody

          -  Active autoimmune disease or a documented history of autoimmune disease or syndrome
             that requires systemic steroids or immunosuppressive agents

          -  Active infection requiring systemic therapy

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Known history of or positive for Hepatitis B or C

          -  Known psychiatric or substance abuse disorder

          -  Regular user (including recreational use) of illicit drugs or had a recent history
             (within the last year) of substance abuse (including alcohol)

          -  Pregnant or breastfeeding, or expecting to conceive, or father children within the
             projected duration of the study

          -  Received a live vaccine within 30 days prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.</citation>
    <PMID>25891173</PMID>
  </reference>
  <results_reference>
    <citation>Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.</citation>
    <PMID>28822576</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>December 9, 2015</results_first_submitted>
  <results_first_submitted_qc>December 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2016</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>PD1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PDL1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=3475-006&amp;kw=3475-006&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment to the study has stopped; some participants are still receiving treatment.</recruitment_details>
      <pre_assignment_details>These results are based on a database cutoff date of 03 Mar 2015, at which time, 497 participants were continuing in the study.
These data were collected and analyzed prior to the 02 Aug 2016 effective date of Amendment 05.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ipilimumab</title>
          <description>Participants receive ipilimumab, 3 mg/kg intravenously (IV), once eveery 3 weeks (Q3W) for a total of 4 doses</description>
        </group>
        <group group_id="P2">
          <title>Pembrolizumab Q2W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to 2 years</description>
        </group>
        <group group_id="P3">
          <title>Pembrolizumab Q3W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Remain on study</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="176"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) population consisted of all randomized participants. Participants were included in the group to which they were randomized for Baseline Characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Ipilimumab</title>
          <description>Participants receive ipilimumab, 3 mg/kg IV, Q3W for a total of 4 doses</description>
        </group>
        <group group_id="B2">
          <title>Pembrolizumab Q2W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, Q2W for up to 2 years</description>
        </group>
        <group group_id="B3">
          <title>Pembrolizumab Q3W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="278"/>
            <count group_id="B2" value="279"/>
            <count group_id="B3" value="277"/>
            <count group_id="B4" value="834"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="14.2"/>
                    <measurement group_id="B2" value="59.9" spread="14.6"/>
                    <measurement group_id="B3" value="61.2" spread="13.6"/>
                    <measurement group_id="B4" value="60.3" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="337"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded independent central radiologic and clinical review using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5mm or the appearance of new lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</description>
        <time_frame>Up to 2 years</time_frame>
        <population>The ITT population, comprising all participants as randomized to a study arm; data collected up to 3 September 2014.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants receive ipilimumab, 3 mg/kg IV, Q3W for a total of 4 doses</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q2W for up to 2 years</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded independent central radiologic and clinical review using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5mm or the appearance of new lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</description>
          <population>The ITT population, comprising all participants as randomized to a study arm; data collected up to 3 September 2014.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.4" upper_limit="6.9"/>
                    <measurement group_id="O3" value="4.1" lower_limit="2.9" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75869</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause. The reported percentage is estimated using a product-limit (Kaplan-Meier) method for censored data; for participants whose survival data was obtained after the data cut-off date for the interim analysis, data were censored at the date of cut-off (3 March 2015). Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</description>
        <time_frame>Month 12</time_frame>
        <population>The ITT population, comprising all participants as randomized to a study arm; data collected up to 3 March 2015.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants receive ipilimumab, 3 mg/kg IV, Q3W for a total of 4 doses</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q2W for up to 2 years</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death due to any cause. The reported percentage is estimated using a product-limit (Kaplan-Meier) method for censored data; for participants whose survival data was obtained after the data cut-off date for the interim analysis, data were censored at the date of cut-off (3 March 2015). Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</description>
          <population>The ITT population, comprising all participants as randomized to a study arm; data collected up to 3 March 2015.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="51.8" upper_limit="64.0"/>
                    <measurement group_id="O2" value="74.1" lower_limit="68.5" upper_limit="78.9"/>
                    <measurement group_id="O3" value="68.4" lower_limit="62.5" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00052</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00358</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51319</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR) or partial response (PR) based on blinded independent central radiologic and clinical review using RECIST 1.1. CR was defined as disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm. PR was defined as a 30% or greater decrease in the sum of diameters of target lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</description>
        <time_frame>Up to 2 years</time_frame>
        <population>The ITT population, comprising all participants randomized to a study arm; data collected through 3 September 2014.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants receive ipilimumab, 3 mg/kg IV, Q3W for a total of 4 doses</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q2W for up to 2 years</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR) or partial response (PR) based on blinded independent central radiologic and clinical review using RECIST 1.1. CR was defined as disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm. PR was defined as a 30% or greater decrease in the sum of diameters of target lesions.
Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</description>
          <population>The ITT population, comprising all participants randomized to a study arm; data collected through 3 September 2014.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.3" upper_limit="16.3"/>
                    <measurement group_id="O2" value="33.7" lower_limit="28.2" upper_limit="39.6"/>
                    <measurement group_id="O3" value="32.9" lower_limit="27.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00013</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>16.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.8</ci_lower_limit>
            <ci_upper_limit>24.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00002</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>25.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82636</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for 30 days after the last dose of study drug (up to 25 months.</time_frame>
      <desc>Data cut-off 3 March 2015; AEs were recorded for the all participants as treated (APaT) population, defined as all randomized patients who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ipilimumab 3 mg/kg Q3W</title>
          <description>Participants receive ipilimumab, 3 mg/kg IV, Q3W for a total of 4 doses</description>
        </group>
        <group group_id="E2">
          <title>Pembrolizumab 10 mg/kg Q2W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, Q2W for up to 2 years</description>
        </group>
        <group group_id="E3">
          <title>Pembrolizumab 10 mg/kg Q3W</title>
          <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Autoimmune pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Stomatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Wound decomposition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood corticotrophin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intraocular pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Desmoplastic melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Axonal neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Horner's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="254" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E3" events="31" subjects_affected="29" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="256"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="278"/>
                <counts group_id="E3" events="29" subjects_affected="28" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="256"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="256"/>
                <counts group_id="E2" events="65" subjects_affected="52" subjects_at_risk="278"/>
                <counts group_id="E3" events="47" subjects_affected="41" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="103" subjects_affected="76" subjects_at_risk="256"/>
                <counts group_id="E2" events="141" subjects_affected="86" subjects_at_risk="278"/>
                <counts group_id="E3" events="114" subjects_affected="77" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="72" subjects_affected="61" subjects_at_risk="256"/>
                <counts group_id="E2" events="87" subjects_affected="74" subjects_at_risk="278"/>
                <counts group_id="E3" events="82" subjects_affected="68" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="256"/>
                <counts group_id="E2" events="57" subjects_affected="41" subjects_at_risk="278"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="38" subjects_at_risk="256"/>
                <counts group_id="E2" events="103" subjects_affected="56" subjects_at_risk="278"/>
                <counts group_id="E3" events="62" subjects_affected="49" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="87" subjects_affected="82" subjects_at_risk="256"/>
                <counts group_id="E2" events="123" subjects_affected="94" subjects_at_risk="278"/>
                <counts group_id="E3" events="121" subjects_affected="95" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="21" subjects_affected="13" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="256"/>
                <counts group_id="E2" events="52" subjects_affected="38" subjects_at_risk="278"/>
                <counts group_id="E3" events="30" subjects_affected="21" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" events="45" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E3" events="31" subjects_affected="27" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" events="30" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="46" subjects_affected="42" subjects_at_risk="256"/>
                <counts group_id="E2" events="60" subjects_affected="47" subjects_at_risk="278"/>
                <counts group_id="E3" events="57" subjects_affected="55" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="278"/>
                <counts group_id="E3" events="25" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="256"/>
                <counts group_id="E2" events="101" subjects_affected="58" subjects_at_risk="278"/>
                <counts group_id="E3" events="59" subjects_affected="56" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="256"/>
                <counts group_id="E2" events="54" subjects_affected="46" subjects_at_risk="278"/>
                <counts group_id="E3" events="37" subjects_affected="34" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" events="52" subjects_affected="40" subjects_at_risk="278"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="278"/>
                <counts group_id="E3" events="27" subjects_affected="23" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="256"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="256"/>
                <counts group_id="E2" events="80" subjects_affected="52" subjects_at_risk="278"/>
                <counts group_id="E3" events="61" subjects_affected="42" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="256"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="256"/>
                <counts group_id="E2" events="77" subjects_affected="58" subjects_at_risk="278"/>
                <counts group_id="E3" events="61" subjects_affected="52" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="256"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="278"/>
                <counts group_id="E3" events="35" subjects_affected="35" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="90" subjects_affected="74" subjects_at_risk="256"/>
                <counts group_id="E2" events="96" subjects_affected="66" subjects_at_risk="278"/>
                <counts group_id="E3" events="73" subjects_affected="58" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="48" subjects_affected="43" subjects_at_risk="256"/>
                <counts group_id="E2" events="87" subjects_affected="59" subjects_at_risk="278"/>
                <counts group_id="E3" events="81" subjects_affected="57" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="278"/>
                <counts group_id="E3" events="41" subjects_affected="39" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

